Skip to main content
    N

    Neuraxis, Inc. (NRXS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $4.62
    -0.18 (-3.75%)

    Market Cap: $68.13M

    Last updated: Nov 17, 2026 at 4:23 PM ET

    Neuraxis, Inc. (NRXS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Neuraxis (NRXS) has a market cap of $68.13M and an enterprise value of $63.86M. It kept -185.24% of revenue as net income over the last 12 months. Its share count is up 31.45% from a year earlier.

    Total Valuation

    Enterprise value is 6.27% below the market cap, as cash exceeds debt.

    Market Cap$68.13M
    Enterprise Value$63.86M
    Latest price (Nov 17, 2026)$4.62

    Key Dates

    The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 17, 2027 (expected)
    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 7.14% in the quarter ended Sep 30, 2026 and grew 34.55% a year over 2 years.

    Shares Outstanding12.99M
    Shares Change (YoY)+31.45%
    Shares Change (QoQ)+7.14%
    Share Count Growth (2Y CAGR)+34.55%

    Valuation Ratios

    Sales and book value multiples are 9.2x and 16.6x. Its year-end P/S ranged from 5.8x to 11.0x from 2023 to 2025.

    P/S Ratio9.2x
    Forward P/S8.7x
    P/B Ratio16.6x
    P/TBV Ratio17.9x

    Valuation history and multiples

    Price Statistics

    The stock is up 97.44% over 52 weeks and trades 32.36% below its 50-day average.

    Beta (1Y)1.68
    52-Week Change+97.44%
    1-Month Change-41.15%
    3-Month Change-27.59%
    6-Month Change-36.28%
    Total Return (1Y)+97.44%
    Total Return (3Y CAGR)+24.91%
    Return vs SPY (1Y)+80.94%
    Max Drawdown (1Y)-47.56%
    Max Drawdown (3Y)-57.89%
    Sharpe Ratio (1Y)0.90
    Correlation with SPY (1Y)0.32
    50-Day Average$6.83
    200-Day Average$6.75
    52-Week Range$2.21 to $9.33
    RSI (14 Days)25.9
    Average Volume (20 Days)146.58K

    Price chart

    Financial Position

    Current assets cover 2.10x current liabilities, and total debt is 0.06x shareholder equity.

    Current Ratio2.10x
    Quick Ratio2.01x
    Debt / Equity0.06x
    Interest Coverage-126.72x

    Returns and Efficiency

    Return on invested capital is -247.67% and return on equity is -334.07% over the last 12 months.

    Return on Equity (ROE)-334.07%
    Return on Assets (ROA)-181.84%
    Return on Invested Capital (ROIC)-247.67%
    Return on Capital Employed (ROCE)-318.72%
    Asset Turnover1.05x
    Inventory Turnover3.40x
    Receivables Turnover10.52x
    Cash Conversion Cycle-98 days

    Scores

    NRXS has an Altman Z-Score of -8.60, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-8.60
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $6.53M over the last 12 months is up 94.29% from the 12 months before.

    Revenue$6.53M
    Revenue Growth (YoY)+94.29%
    Gross Profit$5.63M
    Operating Income-$12.16M
    Pretax Income-$12.10M
    Net Income-$12.10M
    EBITDA-$11.93M
    EBIT-$12.01M
    Reported EPS (TTM)-$0.99

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 54.35% of the $6.66M in total assets.

    Cash and Equivalents$4.48M
    Total Debt$207.31K
    Net Cash$4.27M
    Net Cash Per Share$0.33
    Working Capital$3.16M
    Shareholder Equity$3.62M
    Book Value Per Share$0.28
    Tangible Book Value$3.36M
    Tangible Book Per Share$0.26
    Total Assets$6.66M
    Total Liabilities$3.03M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$6.46M
    FCF Per Share-$0.52
    Depreciation and Amortization$73.84K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -186.16%.

    Gross Margin86.16%
    Operating Margin-186.16%
    Pretax Margin-185.24%
    Net Margin-185.24%
    EBITDA Margin-182.66%
    EBIT Margin-183.79%
    Gross Margin (5Y Average)86.03%

    Growth

    Revenue grew 9.96% a year over 3 years.

    Revenue Growth (3Y CAGR)+9.96%
    Revenue Growth (5Y CAGR)+13.08%

    Revenue and profit by year

    Peer Position

    Against 6 similar companies, NRXS has the 4th highest P/S.

    P/S Ratio9.2x vs 16.7x median
    ROIC-247.67% vs -260.49% median
    Revenue Growth (Trailing 4 Quarters, YoY)+94.29% vs -99.99% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 109.73% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+109.73%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NRXS

    What is NRXS's market cap?

    Neuraxis has a market cap of $68.13M. Its enterprise value, which adds debt and subtracts cash, is $63.86M.

    How many shares of NRXS are outstanding?

    Neuraxis has 12.99M shares outstanding. The count is up 31.45% from a year earlier.

    Does NRXS pay a dividend?

    No. Neuraxis does not pay a dividend.

    How much debt does NRXS have?

    Neuraxis has $207.31K of total debt and $4.48M of cash and equivalents, a net cash position of $4.27M.